Follow
Jonathan J Keats
Jonathan J Keats
Verified email at tgen.org - Homepage
Title
Cited by
Cited by
Year
Initial genome sequencing and analysis of multiple myeloma
MA Chapman, MS Lawrence, JJ Keats, K Cibulskis, C Sougnez, ...
Nature 471 (7339), 467-472, 2011
16872011
Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma
JJ Keats, R Fonseca, M Chesi, R Schop, A Baker, WJ Chng, S Van Wier, ...
Cancer cell 12 (2), 131-144, 2007
12072007
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy
JG Lohr, P Stojanov, SL Carter, P Cruz-Gordillo, MS Lawrence, D Auclair, ...
Cancer cell 25 (1), 91-101, 2014
10892014
Clonal competition with alternating dominance in multiple myeloma
JJ Keats, M Chesi, JB Egan, VM Garbitt, SE Palmer, E Braggio, ...
Blood, The Journal of the American Society of Hematology 120 (5), 1067-1076, 2012
7762012
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling
S Vallabhapurapu, A Matsuzawa, WZ Zhang, PH Tseng, JJ Keats, ...
Nature immunology 9 (12), 1364-1370, 2008
7242008
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
JB Egan, CX Shi, W Tembe, A Christoforides, A Kurdoglu, S Sinari, ...
Blood, The Journal of the American Society of Hematology 120 (5), 1060-1066, 2012
5002012
In multiple myeloma, t (4; 14)(p16; q32) is an adverse prognostic factor irrespective of FGFR3 expression
JJ Keats, T Reiman, CA Maxwell, BJ Taylor, LM Larratt, MJ Mant, ...
Blood, The Journal of the American Society of Hematology 101 (4), 1520-1529, 2003
4952003
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, FE Davies, ...
Blood, The Journal of the American Society of Hematology 132 (6), 587-597, 2018
4012018
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma
C Leung-Hagesteijn, N Erdmann, G Cheung, JJ Keats, AK Stewart, ...
Cancer cell 24 (3), 289-304, 2013
3972013
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, F Davies, ...
Leukemia 33 (1), 159-170, 2019
3962019
Classical and/or alternative NF-κB pathway activation in multiple myeloma
YN Demchenko, OK Glebov, A Zingone, JJ Keats, PL Bergsagel, ...
Blood, The Journal of the American Society of Hematology 115 (17), 3541-3552, 2010
3442010
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma
M Affer, M Chesi, WD Chen, JJ Keats, YN Demchenko, K Tamizhmani, ...
Leukemia 28 (8), 1725-1735, 2014
2712014
RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability
CA Maxwell, JJ Keats, M Crainie, X Sun, T Yen, E Shibuya, M Hendzel, ...
Molecular biology of the cell 14 (6), 2262-2276, 2003
2462003
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
G Ledergor, A Weiner, M Zada, SY Wang, YC Cohen, ME Gatt, N Snir, ...
Nature medicine 24 (12), 1867-1876, 2018
2132018
Overexpression of transcripts originating from the MMSET locus characterizes all t (4; 14)(p16; q32)-positive multiple myeloma patients
JJ Keats, CA Maxwell, BJ Taylor, MJ Hendzel, M Chesi, PL Bergsagel, ...
Blood 105 (10), 4060-4069, 2005
1992005
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-κB signaling pathways in Waldenstrom's macroglobulinemia
E Braggio, JJ Keats, X Leleu, S Van Wier, VH Jimenez-Zepeda, R Valdez, ...
Cancer research 69 (8), 3579-3588, 2009
1892009
Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity
CA Maxwell, JJ Keats, AR Belch, LM Pilarski, T Reiman
Cancer research 65 (3), 850-860, 2005
1622005
High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma
A Miller, Y Asmann, L Cattaneo, E Braggio, J Keats, D Auclair, S Lonial, ...
Blood cancer journal 7 (9), e612-e612, 2017
1462017
UTX/KDM6A loss enhances the malignant phenotype of multiple myeloma and sensitizes cells to EZH2 inhibition
T Ezponda, D Dupéré-Richer, CM Will, EC Small, N Varghese, T Patel, ...
Cell reports 21 (3), 628-640, 2017
1322017
MYC dysregulation in the progression of multiple myeloma
K Misund, N Keane, CK Stein, YW Asmann, G Day, S Welsh, SA Van Wier, ...
Leukemia 34 (1), 322-326, 2020
1312020
The system can't perform the operation now. Try again later.
Articles 1–20